Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20104610 | 0.87 | MEN1 (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL24529722 | 0.87 | MEN1 (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20104607 | 0.85 | MEN1 (0.31) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20104600 | 0.83 | MEN1 (0.35) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL13971374 | 0.80 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20468086 | 0.80 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL21941031 | 0.78 | MEN1 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL19889392 | 0.75 | MEN1 (0.43) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL16260138 | 0.75 | MEN1 (0.39) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL23489658 | 0.75 | ITGB3 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICS NV (BE) | 2021-03-30 | — | — | US | disclosed |
| US-10875902-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-29 | — | — | US | disclosed |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-20190330296-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | MEN1 1346/4885CYP1A2 4129/4885KMT2A 2517/4885 |
| US-10875902-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | GLP1R, GIPR, IAPP | MEN1 1397/4885CYP1A2 4757/4885KMT2A 3695/4885 |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | MEN1 1346/4885CYP1A2 4129/4885KMT2A 2517/4885 |
| US-20190330296-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | GLP1R, GIPR, IAPP | MEN1 1397/4885CYP1A2 4757/4885KMT2A 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.